{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "import httpx"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "URL = \"https://clinicaltrials.gov/api/v2\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "response = httpx.get(URL + \"/studies\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT00072579', 'orgStudyIdInfo': {'id': 'CCCWFU-23102'}, 'secondaryIdInfos': [{'id': 'CDR0000340983', 'type': 'REGISTRY', 'domain': 'PDQ (Physician Data Query)'}, {'id': 'BRLX-02153'}, {'id': 'NCI-7350'}], 'organization': {'fullName': 'Wake Forest University Health Sciences', 'class': 'OTHER'}, 'briefTitle': 'Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment', 'officialTitle': 'Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy'}, 'statusModule': {'statusVerifiedDate': '2013-06', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2003-05'}, 'primaryCompletionDateStruct': {'date': '2006-04', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2003-11-04', 'studyFirstSubmitQcDate': '2003-11-04', 'studyFirstPostDateStruct': {'date': '2003-11-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-01-17', 'lastUpdatePostDateStruct': {'date': '2017-01-19', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Wake Forest University Health Sciences', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia.\\n\\nPURPOSE: This phase II trial is studying sargramostim to see how well it works in treating patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic remission after initial treatment.', 'detailedDescription': 'OBJECTIVES:\\n\\n* Determine the efficacy and safety of sargramostim (GM-CSF) by cytogenetic examination of the bone marrow in patients with chronic phase chronic myelogenous leukemia who are not in complete cytogenetic remission after initial therapy.\\n\\nOUTLINE: Patients receive sargramostim (GM-CSF) subcutaneously daily for 3 months in the absence of disease progression or unacceptable toxicity. Patients achieving no response receive GM-CSF for an additional 3 months. Patients failing to achieve a partial response or better after the second course of GM-CSF are removed from the study. Patients achieving a partial response after the first or second course of GM-CSF continue to receive GM-CSF for an additional 9 months. Patients are then re-evaluated. Patients achieving a complete cytologic response at 9 months then receive GM-CSF 3 times weekly in the absence of disease progression or unacceptable toxicity.\\n\\nPatients are followed every 2 weeks.\\n\\nPROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study within 3 years.'}, 'conditionsModule': {'conditions': ['Leukemia'], 'keywords': ['chronic phase chronic myelogenous leukemia', 'chronic myelogenous leukemia, BCR-ABL1 positive']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}}, 'armsInterventionsModule': {'interventions': [{'type': 'BIOLOGICAL', 'name': 'sargramostim'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cytogenetic response (complete and partial)'}], 'secondaryOutcomes': [{'measure': 'Toxicity as assessed by the Expanded Common Toxicity Criteria v2.0'}, {'measure': 'Time to progression'}, {'measure': 'Survival'}]}, 'eligibilityModule': {'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\\n\\n* Histologically confirmed chronic phase chronic myelogenous leukemia (CML)\\n\\n  * Presence of t(9;22)(q34;q11) with at least 20 cells examined in metaphase by cytogenetic examination of the bone marrow\\n* Complete hematologic remission during prior therapy\\\\* as seen on 2 separate blood count analyses, defined by the following:\\n\\n  * WBC no greater than 10,000/mm\\\\^3 AND platelet count no greater than 450,000/mm\\\\^3\\n  * Disappearance of all signs and symptoms of disease, including palpable splenomegaly\\n  * Normal differential counts (i.e., absence of blasts, promyelocytes, myelocytes, and metamyelocytes) NOTE: \\\\*Continuation of therapy that led to complete hematologic remission is required during study participation\\n* Persistent cytogenetic disease despite 12 months of prior imatinib mesylate therapy, which may have included a trial dose-escalation OR intolerant of imatinib mesylate at a dose greater than 400 mg/day\\n* Not in complete cytogenetic remission within 30 days of study entry\\n\\n  * Persistent Philadelphia chromosome by bone marrow exam\\n\\nPATIENT CHARACTERISTICS:\\n\\nAge\\n\\n* 18 and over\\n\\nPerformance status\\n\\n* ECOG 0-2\\n\\nLife expectancy\\n\\n* More than 6 months\\n\\nHematopoietic\\n\\n* See Disease Characteristics\\n\\nHepatic\\n\\n* Not specified\\n\\nRenal\\n\\n* Not specified\\n\\nOther\\n\\n* Not pregnant or nursing\\n* Fertile patients must use effective contraception\\n* No uncontrolled active infective\\n* No serious medical or psychiatric illness that would prevent giving informed consent or limit survival to less than 6 months\\n* No other malignancy not in remission except curatively treated basal cell skin cancer or carcinoma in situ of the cervix\\n\\nPRIOR CONCURRENT THERAPY:\\n\\nBiologic therapy\\n\\n* Prior sargramostim (GM-CSF) allowed\\n* Prior interferon alfa for CML allowed\\n* No prior stem cell transplantation\\n* Concurrent interferon alfa\\\\* for CML allowed NOTE: \\\\*No dose increase during study participation\\n\\nChemotherapy\\n\\n* At least 4 weeks since prior chemotherapy\\n\\nEndocrine therapy\\n\\n* Not specified\\n\\nRadiotherapy\\n\\n* At least 4 weeks since prior radiotherapy\\n* No concurrent radiotherapy\\n\\nSurgery\\n\\n* At least 4 weeks since prior surgery\\n\\nOther\\n\\n* Prior imatinib mesylate for CML allowed\\n* No other concurrent medication for CML\\n* Concurrent imatinib mesylate\\\\* for CML allowed NOTE: \\\\*No dose increase during study participation', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '120 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Istvan Molnar, MD', 'affiliation': 'Wake Forest University Health Sciences', 'role': 'STUDY_CHAIR'}, {'name': 'Bayard L. Powell, MD', 'affiliation': 'Wake Forest University Health Sciences'}], 'locations': [{'facility': 'CCOP - Western Regional, Arizona', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85006-2726', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'CCOP - Bay Area Tumor Institute', 'city': 'Oakland', 'state': 'California', 'zip': '94609-3305', 'country': 'United States', 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'facility': 'CCOP - Mount Sinai Medical Center', 'city': 'Miami Beach', 'state': 'Florida', 'zip': '33140', 'country': 'United States', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}}, {'facility': 'Regional Radiation Oncology Center at Rome', 'city': 'Rome', 'state': 'Georgia', 'zip': '30165', 'country': 'United States', 'geoPoint': {'lat': 34.25704, 'lon': -85.16467}}, {'facility': 'CCOP - Central Illinois', 'city': 'Decatur', 'state': 'Illinois', 'zip': '62526', 'country': 'United States', 'geoPoint': {'lat': 39.84031, 'lon': -88.9548}}, {'facility': 'Kentuckiana Cancer Institute, PLLC', 'city': 'Louisville', 'state': 'Kentucky', 'zip': '40202', 'country': 'United States', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'facility': 'MBCCOP - LSU Health Sciences Center', 'city': 'New Orleans', 'state': 'Louisiana', 'zip': '70112', 'country': 'United States', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'facility': 'Alamance Cancer Center', 'city': 'Burlington', 'state': 'North Carolina', 'zip': '27216', 'country': 'United States', 'geoPoint': {'lat': 36.09569, 'lon': -79.4378}}, {'facility': 'Hugh Chatham Memorial Hospital', 'city': 'Elkin', 'state': 'North Carolina', 'zip': '28621', 'country': 'United States', 'geoPoint': {'lat': 36.2443, 'lon': -80.8484}}, {'facility': 'Southeastern Medical Oncology Center', 'city': 'Goldsboro', 'state': 'North Carolina', 'zip': '27534-9479', 'country': 'United States', 'geoPoint': {'lat': 35.38488, 'lon': -77.99277}}, {'facility': 'Brody School of Medicine at East Carolina University', 'city': 'Greenville', 'state': 'North Carolina', 'zip': '27858', 'country': 'United States', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'facility': 'Comprehensive Cancer Center at Wake Forest University', 'city': 'Winston-Salem', 'state': 'North Carolina', 'zip': '27157-1096', 'country': 'United States', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'facility': 'CCOP - Columbus', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43206', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Cancer Centers of the Carolinas - Eastside', 'city': 'Greenville', 'state': 'South Carolina', 'zip': '29615', 'country': 'United States', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'facility': 'CCOP - Upstate Carolina', 'city': 'Spartanburg', 'state': 'South Carolina', 'zip': '29303', 'country': 'United States', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000007938', 'term': 'Leukemia'}, {'id': 'D000015464', 'term': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive'}, {'id': 'D000015466', 'term': 'Leukemia, Myeloid, Chronic-Phase'}], 'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D000009369', 'term': 'Neoplasms'}, {'id': 'D000006402', 'term': 'Hematologic Diseases'}, {'id': 'D000007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D000009196', 'term': 'Myeloproliferative Disorders'}, {'id': 'D000001855', 'term': 'Bone Marrow Diseases'}, {'id': 'D000002908', 'term': 'Chronic Disease'}, {'id': 'D000020969', 'term': 'Disease Attributes'}, {'id': 'D000010335', 'term': 'Pathologic Processes'}], 'browseLeaves': [{'id': 'M10945', 'name': 'Leukemia', 'asFound': 'Leukemia', 'relevance': 'HIGH'}, {'id': 'M10955', 'name': 'Leukemia, Myeloid', 'relevance': 'LOW'}, {'id': 'M18123', 'name': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'asFound': 'Chronic myelogenous leukemia', 'relevance': 'HIGH'}, {'id': 'M18125', 'name': 'Leukemia, Myeloid, Chronic-Phase', 'asFound': 'Chronic phase chronic myelogenous leukemia', 'relevance': 'HIGH'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'}, {'id': 'M12149', 'name': 'Myeloproliferative Disorders', 'relevance': 'LOW'}, {'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'}, {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'}, {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}, {'id': 'T3995', 'name': 'Myeloid Leukemia', 'relevance': 'LOW'}, {'id': 'T1309', 'name': 'Chronic Myeloid Leukemia', 'asFound': 'Chronic myelogenous leukemia', 'relevance': 'HIGH'}, {'id': 'T1311', 'name': 'Chronic Myeloproliferative Disorders', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000081222', 'term': 'Sargramostim'}], 'ancestors': [{'id': 'D000007155', 'term': 'Immunologic Factors'}, {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M219218', 'name': 'Sargramostim', 'asFound': 'Increasing', 'relevance': 'HIGH'}, {'id': 'M257633', 'name': 'Molgramostim', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT00517179', 'orgStudyIdInfo': {'id': 'CRE-2006.017-T'}, 'secondaryIdInfos': [{'id': 'HARECCTR0500057'}], 'organization': {'fullName': 'Hospital Authority, Hong Kong', 'class': 'OTHER_GOV'}, 'briefTitle': 'Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS', 'officialTitle': 'Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia'}, 'statusModule': {'statusVerifiedDate': '2011-06', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2006-04'}, 'completionDateStruct': {'date': '2007-05', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2007-08-15', 'studyFirstSubmitQcDate': '2007-08-15', 'studyFirstPostDateStruct': {'date': '2007-08-16', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2011-06-14', 'lastUpdatePostDateStruct': {'date': '2011-06-16', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hospital Authority, Hong Kong', 'class': 'OTHER_GOV'}}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH.'}, 'conditionsModule': {'conditions': ['Prostatic Hyperplasia', 'Impotence'], 'keywords': ['Benign Prostatic Hyperplasia (BPH)', 'Erectile Dysfunction (ED)']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DRUG', 'name': 'Vardenafil 10mg'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo', 'timeFrame': 'From half hour prior to till six hour after administration of the drug (baseline)'}], 'secondaryOutcomes': [{'measure': 'Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP)', 'timeFrame': 'From half hour prior to till six hour after administration of the drug (baseline)'}, {'measure': 'Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug', 'timeFrame': 'From half hour prior to till six hour after administration of the drug (baseline)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Age between 50 to 80 years old\\n* Clinically diagnosed to have lower urinary tract symptoms secondary to BPH:\\n\\n  1. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) \\\\>=8\\n  2. Detectable prostatic enlargement determined by Digital Rectum Examination (DRE)\\n  3. Urinary flow between 5 to 15ml/second in a total void volume \\\\>=150mL\\n* Currently on regular doxazosin GITS once-daily for at least 4 weeks without clinically significant side effects\\n* Complaints of erectile dysfunction with Erectile Function domain (EF) of the International Index of Erectile Function (IIEF) score \\\\<= 21\\n\\nExclusion Criteria:\\n\\n* Congestive heart failure, unstable angina, arrhythmia, myocardial infraction\\n* Hypertension or on any antihypertensive agents\\n* Take nitrate and medication contradicted to vardenafil\\n* Uncontrolled or poorly controlled diabetes mellitus\\n* Intolerance or contra-indicated for the use of vardenafil\\n* Hepatic disorder', 'sex': 'MALE', 'minimumAge': '50 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Chi Fai Ng, Dr', 'affiliation': 'Department of Surgery, Division of Urology, The Chinese University of Hong Kong', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Prince of Wales Hospital', 'city': 'Hong Kong', 'country': 'China', 'geoPoint': {'lat': 22.39407, 'lon': 114.13737}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000007172', 'term': 'Erectile Dysfunction'}, {'id': 'D000011470', 'term': 'Prostatic Hyperplasia'}, {'id': 'D000006965', 'term': 'Hyperplasia'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000012735', 'term': 'Sexual Dysfunction, Physiological'}, {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D000020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D000001523', 'term': 'Mental Disorders'}, {'id': 'D000011469', 'term': 'Prostatic Diseases'}], 'browseLeaves': [{'id': 'M10217', 'name': 'Erectile Dysfunction', 'asFound': 'Erectile Dysfunction', 'relevance': 'HIGH'}, {'id': 'M14334', 'name': 'Prostatic Hyperplasia', 'asFound': 'Prostatic Hyperplasia', 'relevance': 'HIGH'}, {'id': 'M10016', 'name': 'Hyperplasia', 'asFound': 'Hyperplasia', 'relevance': 'HIGH'}, {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'}, {'id': 'M8944', 'name': 'Genital Diseases, Male', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M15546', 'name': 'Sexual Dysfunction, Physiological', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M21873', 'name': 'Sexual Dysfunctions, Psychological', 'relevance': 'LOW'}, {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'}, {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}, {'id': 'M14333', 'name': 'Prostatic Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069058', 'term': 'Vardenafil Dihydrochloride'}], 'ancestors': [{'id': 'D000014665', 'term': 'Vasodilator Agents'}, {'id': 'D000058986', 'term': 'Phosphodiesterase 5 Inhibitors'}, {'id': 'D000010726', 'term': 'Phosphodiesterase Inhibitors'}, {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D000045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000064804', 'term': 'Urological Agents'}], 'browseLeaves': [{'id': 'M19586', 'name': 'Doxazosin', 'relevance': 'LOW'}, {'id': 'M350', 'name': 'Vardenafil Dihydrochloride', 'asFound': 'General practitioner', 'relevance': 'HIGH'}, {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'}, {'id': 'M29332', 'name': 'Phosphodiesterase 5 Inhibitors', 'relevance': 'LOW'}, {'id': 'M13629', 'name': 'Phosphodiesterase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}, {'abbrev': 'Urol', 'name': 'Urological Agents'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT00812279', 'orgStudyIdInfo': {'id': 'YVD-CS01-EU'}, 'organization': {'fullName': 'Philip Morris Products S.A.', 'class': 'INDUSTRY'}, 'briefTitle': 'Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article', 'officialTitle': 'A Controlled, Randomised, Open-label, 3-arm Parallel Single-centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days'}, 'statusModule': {'statusVerifiedDate': '2019-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2008-11'}, 'primaryCompletionDateStruct': {'date': '2009-02', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2009-02', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2008-12-19', 'studyFirstSubmitQcDate': '2008-12-19', 'studyFirstPostDateStruct': {'date': '2008-12-22', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-11-05', 'lastUpdatePostDateStruct': {'date': '2019-11-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Philip Morris Products S.A.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.\\n\\nThe main objective of this study is to compare the biomarkers of exposure to cigarette smoke constituents in smokers switching to SMAR and to biomarkers in smokers of conventional cigarettes (CC). The biomarkers of exposure will be measured in blood and urine samples collected from the subjects. Moreover, the biomarkers in subjects smoking conventional or SMAR cigarettes will be compared with those biomarkers in smokers who stop smoking for 5 days. The short term safety of this new product will also be evaluated.', 'detailedDescription': 'This is a controlled, randomised, open-label, 3-arm parallel single centre confinement study to investigate exposure to selected smoke constituents in smokers switching from CC to SMAR for 5 days.\\n\\n112 eligible subjects will be randomised to the 3 study arms: SMAR, conventional cigarettes (CC) and smoking cessation (SC) in a 2:1:1 ratio.\\n\\nFollowing the screening visit (within 4 weeks prior to the day of admission), the study will be run over an 8-day period in a confined environment, consisting of the admission day (D-2), a 2-day baseline period (D-1 and D0), and a 5-day exposure period (D1 to D5). Subjects will be discharged in the morning of D6. From the discharge of the subject, a 7-day safety follow-up period will be carried out (until D13).'}, 'conditionsModule': {'conditions': ['Smoking'], 'keywords': ['Smokers with acceptable health conditions']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 112, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1. SMAR', 'type': 'EXPERIMENTAL', 'description': 'Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.', 'interventionNames': ['Other: Distillation based smoking article (SMAR cigarette)']}, {'label': '2 Conventional cigarette (CC)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.', 'interventionNames': ['Other: conventional cigarette']}, {'label': '3. smoking cessation (SC)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.', 'interventionNames': ['Other: smoking cessation']}], 'interventions': [{'type': 'OTHER', 'name': 'Distillation based smoking article (SMAR cigarette)', 'description': 'Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.', 'armGroupLabels': ['1. SMAR']}, {'type': 'OTHER', 'name': 'conventional cigarette', 'description': 'Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.', 'armGroupLabels': ['2 Conventional cigarette (CC)']}, {'type': 'OTHER', 'name': 'smoking cessation', 'description': 'Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.', 'armGroupLabels': ['3. smoking cessation (SC)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To demonstrate a reduction in the three primary biomarkers of exposure: Carboxyhaemoglobin concentration in blood, Urinary excretion of S-phenylmercapturic acid and urinary excretion of NNAL and NNAL-glucuronides (total NNAL)', 'timeFrame': '5 days'}], 'secondaryOutcomes': [{'measure': 'To explore changes from baseline COHb, S-PMA, and total NNAL in the three study arms in the course of the study', 'timeFrame': '5 days'}, {'measure': 'To explore changes from baseline in the three study arms with regard to urinary excretion of biomarkers of exposure to several other smoke constituents.', 'timeFrame': '5 days'}, {'measure': 'To assess urinary excretion of nicotine and its five major nicotine metabolites in the three study arms', 'timeFrame': '5 days'}, {'measure': 'To assess nicotine and cotinine concentrations in plasma in the three study arms To compare levels of all biomarkers of exposure in the SMAR arm to those in the smoking cessation (SC) arm', 'timeFrame': '5 days'}, {'measure': 'To assess the mutagenicity potential in urine at the end of the study in the three study arms', 'timeFrame': '5 days'}, {'measure': 'To monitor blood pressure, pulse rate, electrocardiogram, clinical laboratory parameters (standard clinical biochemistry, standard haematology and urine analysis), and adverse events', 'timeFrame': '5 days'}, {'measure': 'To investigate craving and withdrawal symptoms as well as pulmonary symptoms in all three study arms by means of questionnaires', 'timeFrame': '5 days'}, {'measure': 'To investigate change in cytochrome P450 1A2 (CYP1A2) activity from D0 to D5 in the three study arms', 'timeFrame': '5 days'}, {'measure': 'To assess and compare human smoking topography (HST) in smokers before and after switching to SMAR', 'timeFrame': '5 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Caucasian adult smokers (male and female), with acceptable health conditions, aged from 23 to 55 years who usually smoke 10 to 30 non-mentholated conventional cigarettes (with a maximum ISO tar yield of 10 mg) per day, for at least the last 5 consecutive years, will be enrolled in this study.\\n\\nExclusion Criteria:\\n\\n* women of childbearing potential must be excluded if:Subject is pregnant (does not have negative pregnancy tests at screening and at D-2) or breastfeeding/ subject does not agree to use an acceptable method of effective contraception: intrauterine device, intrauterine system, established use of oral/injectable/implantable/ transdermal hormonal methods, barrier methods of contraception (condoms, occlusive caps) with spermicidal foam/gel/film/suppository, vasectomised partner or true abstinence (periodic abstinence and withdrawal are not effective methods) until the end of the safety follow-up period.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '23 Years', 'maximumAge': '55 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Katarzyna Jarus-Dziedzic, MD', 'affiliation': 'MTZ Clinical Research Inc (Warsaw, Poland)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'MTZ Clinical Research Inc.', 'city': 'Warsaw', 'zip': '02-106', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}]}, 'referencesModule': {'references': [{'pmid': '26817490', 'type': 'RESULT', 'citation': 'Ludicke F, Haziza C, Weitkunat R, Magnette J. Evaluation of Biomarkers of Exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study. Nicotine Tob Res. 2016 Jul;18(7):1606-13. doi: 10.1093/ntr/ntw022. Epub 2016 Jan 27.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M12478', 'name': 'Nicotine', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT03878979', 'orgStudyIdInfo': {'id': 'J1923'}, 'secondaryIdInfos': [{'id': 'IRB00207577', 'type': 'OTHER', 'domain': 'JHM IRB'}, {'id': 'CA209-9H7', 'type': 'OTHER', 'domain': 'Bristol-Myers Squibb'}], 'organization': {'fullName': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'class': 'OTHER'}, 'briefTitle': 'Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN', 'officialTitle': 'Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-07-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-10-17', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-10-17', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2019-03-15', 'studyFirstSubmitQcDate': '2019-03-15', 'studyFirstPostDateStruct': {'date': '2019-03-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-15', 'lastUpdatePostDateStruct': {'date': '2024-02-20', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins', 'class': 'OTHER'}, 'collaborators': [{'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).', 'detailedDescription': 'This research is being done to see if it is safe and feasible to give the investigational drugs, nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN). Patients with recurrent disease may have a limited number of sites of metastatic (spread) squamous cell carcinoma of head and neck. Another goal of this study is to learn how nivolumab impacts the immune system\\'s ability to treat the cancer. While nivolumab is approved by the U. S. Food and Drug Administration (FDA) for the treatment of patients with metastatic SCCHN with progression on or after platinum-based chemotherapy, the word \"investigational\" in this context means that the study drugs are not approved by the FDA for the treatment of head and neck cancers prior to surgery and thus is still being tested in research studies. However, the FDA is allowing the use of nivolumab in this study.\\n\\nThis study will have two arms. Cohort (arm) 1 will examine one dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN. Twelve patients will be enrolled to this arm. Cohort 2 will examine one dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred and possibly spread to distant sites, but still can be resected with one surgery. Twelve patients will be enrolled to this arm.'}, 'conditionsModule': {'conditions': ['Head and Neck Squamous Cell Carcinoma', 'Head and Neck Cancer', 'Head and Neck Cancer Metastatic']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The study will accrue to 2 cohorts, each of which consists of about 12 patients. If enrollment on 1 cohort is significantly faster, the lesser enrolling cohort number of patients may be decreased in favor of the better enrolling cohort to keep the total number of evaluable patients at 24 patients.Total of 24 patients will be accrued to the study.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 26, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Newly diagnosed SCCHN', 'type': 'EXPERIMENTAL', 'description': 'One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.', 'interventionNames': ['Drug: Nivolumab 480mg and surgical resection']}, {'label': 'Reccurence of SCCHN', 'type': 'EXPERIMENTAL', 'description': 'One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.', 'interventionNames': ['Drug: Nivolumab 480mg and surgical resection']}], 'interventions': [{'type': 'DRUG', 'name': 'Nivolumab 480mg and surgical resection', 'description': 'One dose of Nivolumab 480mg given four weeks prior to surgical resection.', 'armGroupLabels': ['Newly diagnosed SCCHN', 'Reccurence of SCCHN'], 'otherNames': ['Opdivo', 'ONO-4538', 'BMS-936558', 'MDX 1106']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety as measured by number of participants with drug-related adverse events', 'description': 'Safety of neoadjuvant nivolumab administration in patients with newly diagnosed head and neck cancer and those with locoregional recurrence or oligometastatic disease undergoing surgical resection measured by number of participants with drug related adverse events as defined by CTCAE v5.0, occurring up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer)', 'timeFrame': 'Up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer)'}, {'measure': 'Feasibility as measured by number of participants with successful completion of preoperative treatment and no extended treatment-related delays', 'description': 'Feasibility of neoadjuvant nivolumab administration in patients with newly diagnosed head and neck cancer and those with locoregional recurrence or oligometastatic disease undergoing surgical resection, measured by number of participants with successful completion of preoperative treatment and proceeding to surgery without any extended treatment related delays more than \\\\> 28 days from pre-planned day 0.', 'timeFrame': 'Up to 100 days after the last dose of nivolumab or 30 days after surgery (whichever is longer)'}], 'secondaryOutcomes': [{'measure': 'Major pathologic response rate', 'description': 'Number of participants with \\\\< 10% residual tumor in the resection specimen.', 'timeFrame': 'Day 0 (after surgery)'}, {'measure': 'Progression free survival (PFS)', 'description': 'Number of months until radiologic or clinical progression or death, whichever occurs first.', 'timeFrame': 'up to 3 years'}, {'measure': 'Radiographic response rate', 'description': 'Number of participants with response as determined by RECIST version 1.1 and immune-related response criteria (irRC). Per RECIST criteria, Complete response (CR) is a disappearance of all target lesions, Partial response (PR) is \\\\>= 30% decrease in the sum of the largest diameter (LD) of target lesions, Progressive disease (PD) is \\\\>= 20% increase in the sum of the LD of target lesions.\\n\\nPer irRC, immune-related Complete Response (irCR) is the disappearance of all lesions, measured or unmeasured, and no new lesions; an immune-related Partial Response (irPR) is a 50% drop in tumour burden from baseline as defined by the irRC; and immune-related Progressive Disease (irPD) is a 25% increase in tumour burden from the lowest level recorded.', 'timeFrame': 'up to 4 weeks post-intervention'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion:\\n\\nCohort 1: Subjects must have histologically confirmed previously untreated squamous cell carcinoma of the head and neck which is amenable to surgical resection as part of standard of care.\\n\\nCohort 2: Subjects must have histologically confirmed recurrent squamous cell carcinoma of head and neck, which is amenable for salvage surgery. Sites of recurrence may either be locoregional or distant if resection can be done ideally in one surgical field.\\n\\n* The primary site should be a head and neck squamous cell carcinoma (including, but not limited to oral cavity, oropharynx, hypopharynx, or larynx, paranasal sinuses, nasal cavity). Squamous cell carcinoma of unknown primary, diagnosed in lymph nodes in neck, can be included but should be tested for p16 and confirmed specific assay.\\n* Subjects with oropharyngeal primary tumors must have confirmation of human papillomavirus (HPV) tumor status per clinical standards, although not necessary at enrollment.\\n* Subjects must have been determined to be candidates for surgical resection by a multidisciplinary team including a surgeon, a medical oncologist and a radiation oncologist.\\n* Subjects must have at least one lesion that can be biopsied at baseline.\\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\\n* Age \\\\>18 years.\\n* Life expectancy of greater than 6 months.\\n* Patients must have normal organ and marrow function as defined below:\\n\\n  * leukocytes ≥ 1,500/ microliter (mcL)\\n  * absolute neutrophil count ≥ 1,000/mcL\\n  * platelets ≥ 100,000/mcL\\n  * total bilirubin ≤ 1.5 X institutional upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin \\\\< 3.0 mg/dL)\\n  * AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal\\n  * Creatinine OR creatinine clearance within normal institutional limits OR ≥ 40 mL/min (using modified Cockcroft-Gault formula) for patients with creatinine levels above institutional normal.\\n* Resting and walking O2 saturation must remain above 90% at the time of screening\\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.\\n* Women must not be breastfeeding\\n* Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment and for 5 months post-treatment completion. Women should use an adequate method(s) of contraception (Refer to nivolumab IB for WOCBP and methods of contraception to be provided)\\n* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception (Refer to protocol appendix E) for the duration of treatment with study treatment(s) and 7 months post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time. Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception\\n* Patient understands the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form. Voluntary signed and dated IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines must be obtained before the performance of any protocol related procedures that are not part of normal patient care. Subjects must be competent to report adverse events (AEs), understand the drug dosing schedule and use of medications to control AEs.\\n* Measurable disease - either radiologically (per RECIST) or clinically measurable on exam in order to assess treatment response.\\n\\nExclusion Criteria\\n\\n* Any active history of a known autoimmune disease. Subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\\n* Patients who have had prior chemotherapy for newly diagnosed (cohort 1) or recurrent (cohort 2) head and neck cancer. In cohort 2 only, previous perioperative chemotherapy or chemoradiation for the management of localized or locally advanced disease permitted.\\n* Patients who had prior surgical resection of distant metastasis (metastatectomy) within 3 months of enrollment.\\n* Patients who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti CD137, anti-CTLA-4 antibody therapies, any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. Any live / attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella (MMR)) during treatment and until 100 days post last dose.\\n* Patients with uncontrolled brain metastases\\n* Patients with brain metastases must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks without the use of steroids or on stable or decreasing dose of \\\\< 10mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of carcinomatous meningitis are not eligible.\\n* Patients who have an active concurrent malignancy that is not controlled/cured and could impact life expectancy within the next 3 years. E.g. patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma or treated prostate cancer with no evidence of disease progression may be allowed to enroll after review by the study team.\\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, administration of live vaccination in the prior 3 months, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, myocardial infarction or new onset angina within six months of enrollment, or psychiatric illness/social situations that would limit compliance with study requirements.\\n* Women who are pregnant or nursing.\\n* Men with female partners who are not willing to use contraception.\\n* Active infection with hepatitis B or hepatitis C.\\n* Patients with a condition requiring systemic treatment with either corticosteroids (\\\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids and adrenal replacement steroid doses \\\\< 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\\n* Patients Epstein-Barr virus + (EBV+) with nasopharynx carcinoma\\n* Patient with HIV are excluded given the unknown risk of interaction with HAART and the unknown benefit of immunotherapy in this population.\\n* Participants who have received a live / attenuated vaccine within 30 days of first treatment.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Tanguy Lim-Seiwert, MD', 'affiliation': 'Johns Hopkins University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Johns Hopkins Sidney Kimmel Comprehensive Cancer Center', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21287', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000002277', 'term': 'Carcinoma'}, {'id': 'D000002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D000006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D000077195', 'term': 'Squamous Cell Carcinoma of Head and Neck'}], 'ancestors': [{'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D000009369', 'term': 'Neoplasms'}, {'id': 'D000018307', 'term': 'Neoplasms, Squamous Cell'}, {'id': 'D000009371', 'term': 'Neoplasms by Site'}], 'browseLeaves': [{'id': 'M9348', 'name': 'Head and Neck Neoplasms', 'asFound': 'Head and Neck Cancer', 'relevance': 'HIGH'}, {'id': 'M1689', 'name': 'Squamous Cell Carcinoma of Head and Neck', 'asFound': 'Head and Neck Squamous Cell Carcinoma', 'relevance': 'HIGH'}, {'id': 'M14850', 'name': 'Recurrence', 'relevance': 'LOW'}, {'id': 'M5534', 'name': 'Carcinoma', 'asFound': 'Carcinoma', 'relevance': 'HIGH'}, {'id': 'M5550', 'name': 'Carcinoma, Squamous Cell', 'asFound': 'Squamous Cell Carcinoma', 'relevance': 'HIGH'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'M20451', 'name': 'Neoplasms, Squamous Cell', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077594', 'term': 'Nivolumab'}], 'ancestors': [{'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000000970', 'term': 'Antineoplastic Agents'}, {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}, {'id': 'D000045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M2342', 'name': 'Immune Checkpoint Inhibitors', 'relevance': 'LOW'}, {'id': 'M1854', 'name': 'Nivolumab', 'asFound': 'Into', 'relevance': 'HIGH'}, {'id': 'M1346', 'name': 'Antineoplastic Agents, Immunological', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05602779', 'orgStudyIdInfo': {'id': '22-08-7372'}, 'organization': {'fullName': 'University of Notre Dame', 'class': 'OTHER'}, 'briefTitle': 'Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents', 'officialTitle': 'Leveraging Noninvasive Transcutaneous Vagus Nerve Stimulation and Smartphone Technology to Reduce Suicidal Behaviors and Suicide Among Highly Vulnerable Adolescents'}, 'statusModule': {'statusVerifiedDate': '2023-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-10-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-04-15', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-09-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-10-06', 'studyFirstSubmitQcDate': '2022-11-01', 'studyFirstPostDateStruct': {'date': '2022-11-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-29', 'lastUpdatePostDateStruct': {'date': '2023-12-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Theodore Beauchaine', 'investigatorTitle': 'William K Warren Professor of Psychology', 'investigatorAffiliation': 'University of Notre Dame'}, 'leadSponsor': {'name': 'University of Notre Dame', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Rochester', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True, 'isUsExport': False}, 'descriptionModule': {'briefSummary': \"Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence.\\n\\nCurrent face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.\", 'detailedDescription': 'Over the past two decades, suicide rates have increased nearly 35% in the U.S., with upward trends in nearly all demographic groups. Further increases have occurred since the COVID-19 pandemic began. Despite ambitious goals for reducing suicides and significant federal and private investment, suicide rates continue to rise unabated. To date, the predominant approach to mitigating suicide risk in the U.S. is secondary prevention. Typically, these programs identify risk of recurrence among those who have already attempted suicide at least once. Although secondary prevention is crucial, the majority of deaths by suicide occur on first attempt. Thus, targeted primary prevention earlier in development is essential. Most current primary prevention programs are intensive, expensive, and delivered by highly trained mental health providers, who are in short supply. Traditional face-to-face therapy is also unavailable to many who live in underserved communities, and disliked by adolescents, who much prefer digital delivery on their devices. This high-risk, high-reward proposal addresses these limitations and needs. We use an experimental therapeutics approach to evaluate the independent and combined efficacies of two unconventional but scalable interventions: transcutaneous vagus nerve stimulation (tVNS) to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. These low-cost interventions, which hold strong promise but have not been used before, can reach large numbers of adolescents, with much potential to reduce prospective suicide risk. We will enroll 212 adolescents, ages 13-17 years, who show elevations on at least two prominent risk factors for suicide (e.g., self-injury, maltreatment).\\n\\nUsing a 2 × 2 design, adolescents will be assigned randomly to receive 30 days of treatment with:\\n\\n1. tVNS to target emotion dysregulation,\\n2. a peer-support phone app to target social isolation,\\n3. tVNS + a peer-support phone app, or\\n4. enhanced treatment as usual with monitoring and access to resources.\\n\\nIntervention effects on mechanisms (emotion dysregulation, social isolation) proximal efficacy signals (e.g., physiological reactivity, self-harm) and target outcomes (suicidal ideation, suicidal behaviors) will be evaluated immediately post-intervention and at one-year follow-up. Treatment data will be monitored daily to fine-tune dosing of both interventions. This transformative and innovative proposal tests two novel, scalable preventive interventions designed to \"meet adolescents where they are\" by using digital technologies to address core mechanisms of suicide risk.'}, 'conditionsModule': {'conditions': ['Self Harm', 'Suicidal Ideation'], 'keywords': ['Self Harm', 'Suicide Prevention']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'There will be four distinct treatment groups, each participant will be randomly assigned to one of the four groups.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 212, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'tVNS Program', 'type': 'EXPERIMENTAL', 'description': 'Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.', 'interventionNames': ['Device: tVns Program']}, {'label': 'Phone App Program', 'type': 'EXPERIMENTAL', 'description': \"Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.\", 'interventionNames': ['Other: Phone App Program']}, {'label': 'tVNS and Phone App Program', 'type': 'EXPERIMENTAL', 'description': 'Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.', 'interventionNames': ['Combination Product: tVNS and Phone App Program']}, {'label': 'Enhanced Treatment as Usual', 'type': 'SHAM_COMPARATOR', 'description': 'Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.', 'interventionNames': ['Other: Enhanced Treatment as Usual']}], 'interventions': [{'type': 'DEVICE', 'name': 'tVns Program', 'description': 'Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.', 'armGroupLabels': ['tVNS Program']}, {'type': 'OTHER', 'name': 'Phone App Program', 'description': 'Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.', 'armGroupLabels': ['Phone App Program']}, {'type': 'COMBINATION_PRODUCT', 'name': 'tVNS and Phone App Program', 'description': \"Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.\", 'armGroupLabels': ['tVNS and Phone App Program']}, {'type': 'OTHER', 'name': 'Enhanced Treatment as Usual', 'description': \"Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.\", 'armGroupLabels': ['Enhanced Treatment as Usual']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days', 'description': 'Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge.\\n\\nAll participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.', 'timeFrame': '30 Days'}, {'measure': 'Improved Reports of Social Isolation and Loneliness', 'description': \"Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen.\\n\\nSome teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness.\\n\\nFor the rate of change, we will use percentile ranking vis-a-vis national norms.\", 'timeFrame': '30 Days'}, {'measure': \"Improved Results from Participant's Typical Treatment\", 'description': 'Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm.\\n\\nFor the rate of change, we will use percentile ranking vis-a-vis national norms.', 'timeFrame': '30 Days'}], 'secondaryOutcomes': [{'measure': 'Adherence to tVNS and Phone App intervention from Baseline to 30 days.', 'description': 'Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app.', 'timeFrame': '30 Days'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Aged between 13 and 17 years,\\n* Attend in person meetings in South Bend, IN or Rochester, NY. and,\\n\\nTwo of the following which will be scored during the phone screen:\\n\\n* Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year.\\n* Show high scores on emotional dysregulation\\n* Show high scores on social isolation\\n* Show high scores on impulsivity\\n* Show high scores on depression\\n* Engage in alcohol or other substance use\\n\\nExclusion Criteria:\\n\\n* Parent reported autism or schizophrenia\\n* Implanted pacemaker or cardiac defibrillator, other implanted or metallic device\\n* Pregnant or breast feeding\\n* History of seizures or epilepsy\\n* TMJ Disorder\\n* Bells' Palsy\\n* Impaired cranial nerve function\\n* Facial Pain\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '13 Years', 'maximumAge': '17 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Cheryl Lee, MS', 'role': 'CONTACT', 'phone': '574-631-5097', 'email': 'clee21@nd.edu'}], 'overallOfficials': [{'name': 'Theodore Beauchaine, PhD', 'affiliation': 'William K Warren Foundation Professor of Psychology', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Notre Dame', 'status': 'RECRUITING', 'city': 'South Bend', 'state': 'Indiana', 'zip': '46617', 'country': 'United States', 'contacts': [{'name': 'Jayme Culwell, MSW', 'role': 'CONTACT', 'phone': '574-631-1101', 'email': 'jculwell@nd.edu'}, {'name': 'Cheryl Lee, MS', 'role': 'CONTACT', 'phone': '(574) 631-0950', 'email': 'clee21@nd.edu'}, {'name': 'Theodore P Beauchaine, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Brooke A Ammerman, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Kristin Valentino, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.68338, 'lon': -86.25001}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'There is no plan to share individual participant data outside of the study team.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000059020', 'term': 'Suicidal Ideation'}, {'id': 'D000016728', 'term': 'Self-Injurious Behavior'}], 'ancestors': [{'id': 'D000013405', 'term': 'Suicide'}, {'id': 'D000001526', 'term': 'Behavioral Symptoms'}], 'browseLeaves': [{'id': 'M16191', 'name': 'Suicide', 'relevance': 'LOW'}, {'id': 'M29364', 'name': 'Suicidal Ideation', 'asFound': 'Suicidal Ideation', 'relevance': 'HIGH'}, {'id': 'M19089', 'name': 'Self-Injurious Behavior', 'asFound': 'Self-harm', 'relevance': 'HIGH'}, {'id': 'M2958', 'name': 'Suicide Prevention', 'relevance': 'LOW'}, {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT01126879', 'orgStudyIdInfo': {'id': 'NCI 09U2'}, 'secondaryIdInfos': [{'id': 'NCI-2010-00941'}, {'id': 'STU00019487', 'type': 'OTHER', 'domain': 'Northwestern University IRB'}, {'id': 'P50CA090386', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/P50CA090386'}], 'organization': {'fullName': 'Northwestern University', 'class': 'OTHER'}, 'briefTitle': 'Genistein in Treating Patients With Prostate Cancer', 'officialTitle': 'Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells'}, 'statusModule': {'statusVerifiedDate': '2019-04', 'overallStatus': 'TERMINATED', 'whyStopped': 'Closed due to low accrual', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-02-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2013-05-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-12-28', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2010-05-18', 'studyFirstSubmitQcDate': '2010-05-18', 'studyFirstPostDateStruct': {'date': '2010-05-20', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2019-05-01', 'resultsFirstSubmitQcDate': '2019-06-24', 'resultsFirstPostDateStruct': {'date': '2019-07-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-08-27', 'lastUpdatePostDateStruct': {'date': '2019-09-10', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Northwestern University', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\\n\\nPURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.', 'detailedDescription': 'PRIMARY OBJECTIVES:\\n\\nI. Determine whether genistein treatment will decrease the number of circulating prostate cells (CPCs) in the peripheral blood as measured by qRT-PCR for PSA performed on RNA extracted from peripheral blood mononuclear cells (PBMNCs).\\n\\nSECONDARY OBJECTIVES:\\n\\nI. Determine the natural history of circulating prostate cells (CPCs) in a cohort of subjects prior to and post radical prostatectomy.\\n\\nII. Compare the measurement of PSA between three separate methods: in CPCs by qRT-PCR, in serum by the standard clinical chemistry assay (i.e., ELISA), and in plasma and serum by the nano-PSA assay.\\n\\nIII. Measure the effect of genistein on gene and protein expression in prostate tissue by qRT-PCR and immunohistochemistry, respectively, for the following genes and their respective protein products: HSP27, MMP-2, ALK-2, BASP1, and HCF2.\\n\\nOUTLINE:\\n\\nPatients are randomized to 1 of 2 treatment arms.\\n\\nARM I: Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nARM II: Patients receive oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nAll patients undergo radical prostatectomy at least 2 weeks, but not more than 3 months following the start of therapy.\\n\\nAfter completion of study treatment, patients are followed at 1, 6, and 12 months.'}, 'conditionsModule': {'conditions': ['Adenocarcinoma of the Prostate', 'Recurrent Prostate Cancer', 'Stage I Prostate Cancer', 'Stage II Prostate Cancer', 'Stage III Prostate Cancer']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 12, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Arm I', 'type': 'EXPERIMENTAL', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.', 'interventionNames': ['Dietary Supplement: genistein', 'Procedure: therapeutic conventional surgery']}, {'label': 'Arm II', 'type': 'PLACEBO_COMPARATOR', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.', 'interventionNames': ['Other: placebo', 'Procedure: therapeutic conventional surgery']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'genistein', 'description': 'Given orally', 'armGroupLabels': ['Arm I'], 'otherNames': ['CI 75610', 'Genestein', 'genisteol', 'genisterin', 'prunetol', 'sophoricol']}, {'type': 'OTHER', 'name': 'placebo', 'description': 'Given orally', 'armGroupLabels': ['Arm II'], 'otherNames': ['PLCB']}, {'type': 'PROCEDURE', 'name': 'therapeutic conventional surgery', 'description': 'Radical prostatectomy for treatment of prostate cancer', 'armGroupLabels': ['Arm I', 'Arm II']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs', 'description': \"Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.\", 'timeFrame': 'At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery'}], 'secondaryOutcomes': [{'measure': 'Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy', 'description': 'Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.', 'timeFrame': 'At baseline, 1 and 12 months after surgery'}, {'measure': 'Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue', 'description': 'At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.', 'timeFrame': 'At baseline and at time of surgery'}, {'measure': 'Measurement of PSA in Serum and Plasma by Nanotechnology', 'description': 'Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.', 'timeFrame': 'At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion\\n\\n* Participants must have a pathologic diagnosis of prostate cancer within the past 6 months, have clinical stage T1-3 disease, PSA \\\\>= 10, Gleason score \\\\>= 8, and have elected to undergo radical prostatectomy; those found to have detectable circulating prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to proceed onto the treatment phase of the protocol; pathology slides used for diagnosis will be submitted to the SPORE tissue pathology core for review\\n* ECOG performance status 0-1\\n* Hemoglobin \\\\> 9.0gm/dl\\n* Platelets \\\\>= 100 K/uL\\n* ANC \\\\> 1000/uL\\n* AST (SGOT)/ALT (SGPT) \\\\< 3X upper limit of normal\\n* Creatinine \\\\< 2.0 mg/dl\\n* Total bilirubin \\\\< 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)\\n* Participants must agree not to take soy supplements\\n* Ability to understand and the willingness to sign a written informed consent document\\n* Willingness to take study agent for at least 2 weeks prior to radical prostatectomy\\n\\nExclusion\\n\\n* History of venous thrombosis within past year\\n* Participants must not be receiving active therapy for neoplastic disorders (including hormone or radiation therapy for prostate cancer)\\n* Participants may not be receiving any other investigational agents\\n* Known soy intolerance\\n* Medical conditions that, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained', 'healthyVolunteers': False, 'sex': 'MALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'William Catalona', 'affiliation': 'Northwestern University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Northwestern University', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60611', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}]}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Patients entered the study and were treated in a double blinded fashion with a ration of 2:1 Genistein:Placebo. Unblinding occured if it was medically necessary otherwise blinding was maintained until the time of data review.', 'recruitmentDetails': 'The study opened on October 21, 2010 with an accrual goal of 30 patients with firs the patient enrolled March 3, 2011. The study was designed as a randomized blinded drug/placebo study but was amended to a single arm drug study and accrual reduced to 18. Study closed permanently on May 28, 2014 due to low accrual with 12 patients treated on study.', 'groups': [{'id': 'FG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'FG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Started 3 Months of Genistein/Placebo', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Prostatectomy or Radiation', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Completed 3 Months Genistein/Placebo', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Progressive Disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'BG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive oral genistein or placebo once daily for 3 months beginning at least 2 weeks prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '4'}, {'groupId': 'BG002', 'value': '12'}]}], 'measures': [{'title': 'Age, Categorical', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'groupId': 'BG000', 'value': '5'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '7'}]}, {'title': '>=65 years', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '5'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '4'}, {'groupId': 'BG002', 'value': '12'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '11'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '4'}, {'groupId': 'BG002', 'value': '12'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '4'}, {'groupId': 'BG002', 'value': '12'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs', 'description': \"Blood will be collected to analyze the number of CPC's at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.\", 'populationDescription': 'Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.', 'reportingStatus': 'POSTED', 'timeFrame': 'At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery', 'groups': [{'id': 'OG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'OG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy', 'description': 'Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery.', 'populationDescription': 'Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.', 'reportingStatus': 'POSTED', 'timeFrame': 'At baseline, 1 and 12 months after surgery', 'groups': [{'id': 'OG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'OG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Measure the Effect of Genistein on Select Gene and Protein Expressions in Prostate Tissue', 'description': 'At baseline and time of surgery, tissue will be collected to measure the effect of genistein on select gene and protein expressions in prostate tissue.', 'populationDescription': 'Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.', 'reportingStatus': 'POSTED', 'timeFrame': 'At baseline and at time of surgery', 'groups': [{'id': 'OG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'OG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}, {'type': 'SECONDARY', 'title': 'Measurement of PSA in Serum and Plasma by Nanotechnology', 'description': 'Blood will be collected to measure PSA in serum and plasma by nanotechnology at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery.', 'populationDescription': 'Data was not collected for analysis of this endpoint due to the study closing before the accrual goal was met.', 'reportingStatus': 'POSTED', 'timeFrame': 'At screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery', 'groups': [{'id': 'OG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}, {'id': 'OG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'timeFrame': 'Adverse Events assessed at the following timepoints for the study: at the start of treatment, at surgery or radiation, at clinic visits occurring 1-3 months post-surgery, or post-initiation of radiation therapy, or at 3 months for those not undergoing surgery or radiation, as well as at a 4 month telephone contact.', 'description': 'Adverse events were collected by patient reports', 'eventGroups': [{'id': 'EG000', 'title': 'Arm I - Genistein', 'description': 'Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nGenistein: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer', 'deathsNumAffected': 0, 'deathsNumAtRisk': 8, 'seriousNumAffected': 1, 'seriousNumAtRisk': 8, 'otherNumAffected': 2, 'otherNumAtRisk': 8}, {'id': 'EG001', 'title': 'Arm II - Placebo', 'description': 'Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.\\n\\nPlacebo: Given orally\\n\\nTherapeutic conventional surgery: Radical prostatectomy for treatment of prostate cancer', 'deathsNumAffected': 0, 'deathsNumAtRisk': 4, 'seriousNumAffected': 0, 'seriousNumAtRisk': 4, 'otherNumAffected': 1, 'otherNumAtRisk': 4}], 'seriousEvents': [{'term': 'Atrial Fibrillation', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 4}]}], 'otherEvents': [{'term': 'Pain in Extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 4}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 4}]}, {'term': 'Large pimple', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 4}]}, {'term': 'Emergency right inguinal repair', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 4}]}, {'term': 'Atrial Fibrillation', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 4}]}, {'term': 'INR Increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 8}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 4}]}]}, 'moreInfoModule': {'limitationsAndCaveats': {'description': 'The study was closed by an internal safety and data monitoring committee due to slow accrual of the study.'}, 'certainAgreement': {'piSponsorEmployee': True}, 'pointOfContact': {'title': 'William Catalona, MD', 'organization': 'Northwestern University', 'email': 'WCatalona@nm.org', 'phone': '312-695-1301'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D000005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D000014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D000009371', 'term': 'Neoplasms by Site'}, {'id': 'D000009369', 'term': 'Neoplasms'}, {'id': 'D000005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000011469', 'term': 'Prostatic Diseases'}, {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}], 'browseLeaves': [{'id': 'M14850', 'name': 'Recurrence', 'relevance': 'LOW'}, {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'}, {'id': 'M14335', 'name': 'Prostatic Neoplasms', 'asFound': 'Prostate Cancer', 'relevance': 'HIGH'}, {'id': 'M8946', 'name': 'Genital Neoplasms, Male', 'relevance': 'LOW'}, {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'}, {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'}, {'id': 'M8944', 'name': 'Genital Diseases, Male', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14333', 'name': 'Prostatic Diseases', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000019833', 'term': 'Genistein'}], 'ancestors': [{'id': 'D000016588', 'term': 'Anticarcinogenic Agents'}, {'id': 'D000020011', 'term': 'Protective Agents'}, {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000000970', 'term': 'Antineoplastic Agents'}, {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'}, {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D000045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000048789', 'term': 'Phytoestrogens'}, {'id': 'D000004968', 'term': 'Estrogens, Non-Steroidal'}, {'id': 'D000004967', 'term': 'Estrogens'}, {'id': 'D000006728', 'term': 'Hormones'}, {'id': 'D000006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}], 'browseLeaves': [{'id': 'M21721', 'name': 'Genistein', 'asFound': 'Kinesio Tape', 'relevance': 'HIGH'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}, {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M25995', 'name': 'Phytoestrogens', 'relevance': 'LOW'}, {'id': 'M8116', 'name': 'Estrogens', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': True}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05865379', 'orgStudyIdInfo': {'id': 'BUFY01-CT-2101'}, 'organization': {'fullName': 'TRB Chemedica International SA', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease', 'officialTitle': 'Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease: a Non-inferiority Investigation', 'acronym': 'BUSTON-01'}, 'statusModule': {'statusVerifiedDate': '2023-05', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-10', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-10', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-05-01', 'studyFirstSubmitQcDate': '2023-05-09', 'studyFirstPostDateStruct': {'date': '2023-05-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-22', 'lastUpdatePostDateStruct': {'date': '2023-11-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'TRB Chemedica International SA', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:\\n\\n* Is BUFY01 non-inferior to SVS20 in terms of signs of DED?\\n* Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED?\\n\\nParticipants will be asked to:\\n\\n* Visit the trial site at 4 different timepoints\\n* Use the allocated study treatment everyday until the end of the study (during 3 months)\\n* Be examined by the investigator\\n* Complete several questionnaires\\n* Return unused study treatment.\\n\\nResearchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.'}, 'conditionsModule': {'conditions': ['Dry Eye Disease']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'BUFY01', 'type': 'EXPERIMENTAL', 'description': '0.18% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.3 mL', 'interventionNames': ['Device: BUFY01 eye drops in single-dose containers']}, {'label': 'SVS20', 'type': 'ACTIVE_COMPARATOR', 'description': '0.18% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.3 mL', 'interventionNames': ['Device: SVS20 eye drops in single-dose containers']}], 'interventions': [{'type': 'DEVICE', 'name': 'BUFY01 eye drops in single-dose containers', 'description': '1 to 2 drops in each eye, as often as needed', 'armGroupLabels': ['BUFY01']}, {'type': 'DEVICE', 'name': 'SVS20 eye drops in single-dose containers', 'description': '1 to 2 drops in each eye, as often as needed', 'armGroupLabels': ['SVS20']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Signs', 'description': 'Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome)', 'timeFrame': 'Day 28'}], 'secondaryOutcomes': [{'measure': 'Symptoms', 'description': 'Change from baseline in Ocular Surface Disease Index', 'timeFrame': 'Day 28'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria includes:\\n\\n* At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears;\\n* At least one eye with Oxford score ≥ 4 and ≤ 9;\\n* At least one objective sign of tear deficiency (in at least one eligible eye);\\n* Having a health insurance.\\n\\nExclusion Criteria includes:\\n\\n* Wear of contact lenses starting within the last 2 months;\\n* Best-corrected visual acuity (BCVA) \\\\< 1/10;\\n* Severe DED with one of the listed conditions:\\n* Severe blepharitis;\\n* Seasonal allergy;\\n* Any issues of the ocular surface not related to DED;\\n* History of ocular trauma, infection or inflammation not related to DED;\\n* History of ocular surgery, including laser surgery;\\n* Unstable glaucoma;\\n* Use of artificial tears with preservative within the last 2 weeks;\\n* Systemic (enteral or parenteral) or local (topical) use of one of the listed medications:\\n* Known hypersensitivity to any constituent of the study treatments;\\n* Pregnancy or breastfeeding;\\n* Participation in another clinical study within the last 90 days;\\n* Legally restricted autonomy, freedom of decision and action.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000015352', 'term': 'Dry Eye Syndromes'}, {'id': 'D000007638', 'term': 'Keratoconjunctivitis Sicca'}, {'id': 'D000005128', 'term': 'Eye Diseases'}], 'ancestors': [{'id': 'D000007766', 'term': 'Lacrimal Apparatus Diseases'}, {'id': 'D000007637', 'term': 'Keratoconjunctivitis'}, {'id': 'D000003231', 'term': 'Conjunctivitis'}, {'id': 'D000003229', 'term': 'Conjunctival Diseases'}, {'id': 'D000007634', 'term': 'Keratitis'}, {'id': 'D000003316', 'term': 'Corneal Diseases'}], 'browseLeaves': [{'id': 'M18040', 'name': 'Dry Eye Syndromes', 'asFound': 'Dry Eye Disease', 'relevance': 'HIGH'}, {'id': 'M10664', 'name': 'Keratoconjunctivitis Sicca', 'asFound': 'Dry Eye Disease', 'relevance': 'HIGH'}, {'id': 'M8271', 'name': 'Eye Diseases', 'asFound': 'Eye Disease', 'relevance': 'HIGH'}, {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'}, {'id': 'M10663', 'name': 'Keratoconjunctivitis', 'relevance': 'LOW'}, {'id': 'M10786', 'name': 'Lacrimal Apparatus Diseases', 'relevance': 'LOW'}, {'id': 'M6455', 'name': 'Conjunctivitis', 'relevance': 'LOW'}, {'id': 'M6453', 'name': 'Conjunctival Diseases', 'relevance': 'LOW'}, {'id': 'M10660', 'name': 'Keratitis', 'relevance': 'LOW'}, {'id': 'M6539', 'name': 'Corneal Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000009883', 'term': 'Ophthalmic Solutions'}], 'ancestors': [{'id': 'D000019999', 'term': 'Pharmaceutical Solutions'}], 'browseLeaves': [{'id': 'M9878', 'name': 'Hyaluronic Acid', 'relevance': 'LOW'}, {'id': 'M12814', 'name': 'Ophthalmic Solutions', 'asFound': 'Calcium', 'relevance': 'HIGH'}, {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT03877679', 'orgStudyIdInfo': {'id': 'OMED2:5:1'}, 'organization': {'fullName': 'Cairo University', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients', 'officialTitle': 'The Effect of Topical Curcumin Versus Topical Corticosteroid on Pain, Clinical Parameters and Salivary Level of IL-33 in Oral Lichen Planus Patients: A Randomized Controlled Clinical Trial'}, 'statusModule': {'statusVerifiedDate': '2019-03', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-05-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-05-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-06-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-09-24', 'studyFirstSubmitQcDate': '2019-03-14', 'studyFirstPostDateStruct': {'date': '2019-03-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-03-14', 'lastUpdatePostDateStruct': {'date': '2019-03-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Mohamed salah abd-elhameed', 'investigatorTitle': 'principal investigator', 'investigatorAffiliation': 'Cairo University'}, 'leadSponsor': {'name': 'Cairo University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the management of Oral lichen planus.\\n\\n* Assess the efficacy of this preparation on pain, clinical parameter and the level of IL-33 in saliva.\\n* Compare the outcome of new preparation with the gold standard treatment (corticosteroids).', 'detailedDescription': 'Two groups will be prepared then decision of which one take curcumin paste will be selected according to randomized numbers in a sequentially numbered, opaque, sealed envelope\\n\\n1 group will take topical corticosteroid and 1 will take curcumin paste then IL-33 level in saliva will be measured at the base line and at the end of 4th week pain and clinical parameters will be measured at 2nd and 4th week'}, 'conditionsModule': {'conditions': ['Oral Lichen Planus'], 'keywords': ['oral lichen planus', 'curcumin', 'IL-33', 'corticosteroids']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'Outcome assessor (CS) and statistician', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'turmeric paste', 'type': 'EXPERIMENTAL', 'description': 'Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).', 'interventionNames': ['Drug: Turmeric paste']}, {'label': 'Triamcenolone in orabase', 'type': 'ACTIVE_COMPARATOR', 'description': 'Triamcenolone + na ploycarboxylate', 'interventionNames': ['Drug: Triamcinolone']}], 'interventions': [{'type': 'DRUG', 'name': 'Triamcinolone', 'description': 'Triamcenolone +napolycarboxylate', 'armGroupLabels': ['Triamcenolone in orabase'], 'otherNames': ['Triamcenolone in orabase']}, {'type': 'DRUG', 'name': 'Turmeric paste', 'description': 'Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University', 'armGroupLabels': ['turmeric paste'], 'otherNames': ['Curcumin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain intensity', 'description': 'measured by Visual Analog Scale (VAS) 0 = no pain 10= severe pain 0= no pain 10= pain severe pain', 'timeFrame': '4 weeks'}], 'secondaryOutcomes': [{'measure': 'clinical sign score', 'description': 'measured by Thongprasom from score 0 to 5 0= only white lesion 5=area of erosion more than 2 cm', 'timeFrame': 'Baseline , 2nd week and 4th week'}, {'measure': 'IL-33 level in saliva', 'description': 'by ELISA', 'timeFrame': 'base line and 4th week'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients who will be clinically diagnosed as having atrophic \\\\&/or erosive oral lichen planus.\\n* Patients with controlled diabetes and/or controlled hypertension will be included in the study.\\n* Patients with no history of taking corticosteroids for the last 6 months\\n* Patients who agrees to take medication.\\n\\nExclusion Criteria:\\n\\n* Pregnant and lactating ladies.\\n* Patients with history of topical steroids during last 2 months \\\\& systemic steroids during last 6 months.\\n* Patients with recent dental filling associated with the lesion or associated with recent drug administration.\\n* Patient with uncontrolled diabetes, uncontrolled hypertension, or those with positive HCV ab or HBs Ag.', 'healthyVolunteers': True, 'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'referencesModule': {'references': [{'pmid': '12676044', 'type': 'BACKGROUND', 'citation': 'Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. doi: 10.1089/107555303321223035.'}, {'type': 'BACKGROUND', 'citation': \"Greenberg G, Glick M. Burket's Oral Medicine: Diagnosis and Treatment. Hamilton, Ontario, BC Decker, 11th ed., 2008:90-1\"}, {'pmid': '29510851', 'type': 'BACKGROUND', 'citation': 'Nosratzehi T, Arbabi-Kalati F, Hamishehkar H, Bagheri S. Comparison of the Effects of Curcumin Mucoadhesive Paste and Local Corticosteroid on the Treatment of Erosive Oral Lichen Planus Lesions. J Natl Med Assoc. 2018 Feb;110(1):92-97. doi: 10.1016/j.jnma.2017.01.011. Epub 2017 May 11.'}, {'pmid': '17604143', 'type': 'RESULT', 'citation': 'Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, Weintraub J. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007 Aug;14(7-8):437-46. doi: 10.1016/j.phymed.2007.05.003. Epub 2007 Jul 2.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'All authors of this trial will have access to the final trial dataset.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'after study completion', 'accessCriteria': 'pubmed'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000017676', 'term': 'Lichen Planus, Oral'}, {'id': 'D000008010', 'term': 'Lichen Planus'}], 'ancestors': [{'id': 'D000017512', 'term': 'Lichenoid Eruptions'}, {'id': 'D000017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D000012871', 'term': 'Skin Diseases'}, {'id': 'D000009059', 'term': 'Mouth Diseases'}, {'id': 'D000009057', 'term': 'Stomatognathic Diseases'}], 'browseLeaves': [{'id': 'M19896', 'name': 'Lichen Planus, Oral', 'asFound': 'Oral Lichen Planus', 'relevance': 'HIGH'}, {'id': 'M11012', 'name': 'Lichen Planus', 'asFound': 'Lichen Planus', 'relevance': 'HIGH'}, {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'}, {'id': 'M8219', 'name': 'Exanthema', 'relevance': 'LOW'}, {'id': 'M19775', 'name': 'Lichenoid Eruptions', 'relevance': 'LOW'}, {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'}, {'id': 'M19713', 'name': 'Skin Diseases, Papulosquamous', 'relevance': 'LOW'}, {'id': 'M12019', 'name': 'Mouth Diseases', 'relevance': 'LOW'}, {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'}, {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000014221', 'term': 'Triamcinolone'}, {'id': 'D000003474', 'term': 'Curcumin'}], 'ancestors': [{'id': 'D000000893', 'term': 'Anti-Inflammatory Agents'}, {'id': 'D000005938', 'term': 'Glucocorticoids'}, {'id': 'D000006728', 'term': 'Hormones'}, {'id': 'D000006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D000045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000000894', 'term': 'Anti-Inflammatory Agents, Non-Steroidal'}, {'id': 'D000018712', 'term': 'Analgesics, Non-Narcotic'}, {'id': 'D000000700', 'term': 'Analgesics'}, {'id': 'D000018689', 'term': 'Sensory System Agents'}, {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D000018501', 'term': 'Antirheumatic Agents'}, {'id': 'D000000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'}, {'id': 'M16974', 'name': 'Triamcinolone', 'asFound': 'Inhalation', 'relevance': 'HIGH'}, {'id': 'M16975', 'name': 'Triamcinolone Acetonide', 'relevance': 'LOW'}, {'id': 'M237966', 'name': 'Triamcinolone hexacetonide', 'relevance': 'LOW'}, {'id': 'M209573', 'name': 'Triamcinolone diacetate', 'relevance': 'LOW'}, {'id': 'M6685', 'name': 'Curcumin', 'asFound': 'Gas', 'relevance': 'HIGH'}, {'id': 'M4854', 'name': 'Benzocaine', 'relevance': 'LOW'}, {'id': 'M4292', 'name': 'Antioxidants', 'relevance': 'LOW'}, {'id': 'M342247', 'name': 'Turmeric extract', 'relevance': 'LOW'}, {'id': 'M9047', 'name': 'Glucocorticoids', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M4218', 'name': 'Anti-Inflammatory Agents, Non-Steroidal', 'relevance': 'LOW'}, {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}, {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'}, {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'}, {'id': 'T433', 'name': 'Tannic Acid', 'relevance': 'LOW'}, {'id': 'T319', 'name': 'Turmeric', 'asFound': 'LAR', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}, {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}, {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT03960879', 'orgStudyIdInfo': {'id': 'METHY2'}, 'organization': {'fullName': 'Peking Union Medical College Hospital', 'class': 'OTHER'}, 'briefTitle': 'DNA Methylation for Screening Uterine Cervical Lesions', 'officialTitle': 'DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Prospective Cohort Study'}, 'statusModule': {'statusVerifiedDate': '2019-05', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-06-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-06-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-06-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-05-21', 'studyFirstSubmitQcDate': '2019-05-21', 'studyFirstPostDateStruct': {'date': '2019-05-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-05-22', 'lastUpdatePostDateStruct': {'date': '2019-05-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Lei Li', 'investigatorTitle': 'Professor', 'investigatorAffiliation': 'Peking Union Medical College Hospital'}, 'leadSponsor': {'name': 'Lei Li', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to compare the testing of DNA methylation, high-risk HPV subtypes, and cytology with the definite histological results for uterine cervical lesions in a prospective cohort study.\\n\\nThis study will include 300 unselected patients with definite histological results. All the cervical specimens of cytology collected in the clinical settings will be utilized for the testing of DNA methylation, high-risk HPV subtypes and thin prep liquid-based cytology test (TCT). The sensitivity, specificity, positive predictive value and negative predictive value were calculated based on the known histological results. The differences of DNA methylation with high-risk human papillomavirus (HPV) and TCT will also be analyzed.\\n\\nThe testing of DNA methylation will be performed with the methylation-specific polymerase chain reaction (PCR). The TCT and HPV testing will be performed with the Roche kits.'}, 'conditionsModule': {'conditions': ['DNA Methylation', 'Uterine Cervical Cancer', 'High Grade Squamous Intraepithelial Lesions', 'Low Grade Squamous Intraepithelial Lesions']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Uterine cervical cytology collected during the clinical settings for the testing of DNA methylation, TCT and high-risk HPV'}, 'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'DNA methylation', 'description': 'DNA methylation for the cervical cytology'}, {'type': 'DIAGNOSTIC_TEST', 'name': 'High-risk HPV', 'description': 'High-risk HPV testing for the cervical cytology'}, {'type': 'DIAGNOSTIC_TEST', 'name': 'TCT', 'description': 'Thin prep liquid-based cytology test for the cervical cytology'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Sensitivity of DNA methylation', 'description': 'Sensitivity of DNA methylation compared with histological results for the differentiation of cervical cancer and high grade squamous intraepithelial lesions (HSIL)', 'timeFrame': '1 year'}, {'measure': 'Specificity of DNA methylation', 'description': 'Specificity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL', 'timeFrame': '1 year'}], 'secondaryOutcomes': [{'measure': 'Positive predictive value of DNA methylation', 'description': 'Positive predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL', 'timeFrame': '1 year'}, {'measure': 'Negative predictive value of DNA methylation', 'description': 'Negative predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL', 'timeFrame': '1 year'}, {'measure': 'Correlation coefficient of DNA methylation with other screening methods', 'description': 'Correlation coefficient of DNA methylation with high-risk HPV and TCT results', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Confirmed cervical histology within one month when collecting cervical cytology\\n* Aged 18 years or older\\n* Signed an approved informed consents\\n\\nExclusion Criteria:\\n\\n* Not meeting all of the inclusion criteria', 'healthyVolunteers': False, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': '* Confirmed cervical histology within one month when collecting cervical cytology\\n* Aged 18 years or older', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lei Li', 'role': 'CONTACT', 'phone': '+8613911988831', 'email': 'lilei@163.com'}], 'overallOfficials': [{'name': 'Lei Li, M.D.', 'affiliation': 'Peking Union Medical College Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Lei Li', 'status': 'RECRUITING', 'city': 'Beijing', 'state': 'Beijing', 'zip': '100730', 'country': 'China', 'contacts': [{'name': 'Lei Li, MD', 'role': 'CONTACT', 'phone': '008613911988831', 'email': 'lileigh@163.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000002583', 'term': 'Uterine Cervical Neoplasms'}, {'id': 'D000065310', 'term': 'Squamous Intraepithelial Lesions of the Cervix'}], 'ancestors': [{'id': 'D000014594', 'term': 'Uterine Neoplasms'}, {'id': 'D000005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D000014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D000009371', 'term': 'Neoplasms by Site'}, {'id': 'D000009369', 'term': 'Neoplasms'}, {'id': 'D000002577', 'term': 'Uterine Cervical Diseases'}, {'id': 'D000014591', 'term': 'Uterine Diseases'}, {'id': 'D000005831', 'term': 'Genital Diseases, Female'}, {'id': 'D000052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D000005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000002578', 'term': 'Uterine Cervical Dysplasia'}, {'id': 'D000011230', 'term': 'Precancerous Conditions'}], 'browseLeaves': [{'id': 'M5830', 'name': 'Uterine Cervical Neoplasms', 'asFound': 'Uterine Cervical Cancer', 'relevance': 'HIGH'}, {'id': 'M30502', 'name': 'Squamous Intraepithelial Lesions of the Cervix', 'asFound': 'Squamous Intraepithelial Lesions', 'relevance': 'HIGH'}, {'id': 'M17342', 'name': 'Uterine Neoplasms', 'relevance': 'LOW'}, {'id': 'M8945', 'name': 'Genital Neoplasms, Female', 'relevance': 'LOW'}, {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'}, {'id': 'M5825', 'name': 'Uterine Cervical Diseases', 'relevance': 'LOW'}, {'id': 'M17339', 'name': 'Uterine Diseases', 'relevance': 'LOW'}, {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'}, {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M5826', 'name': 'Uterine Cervical Dysplasia', 'relevance': 'LOW'}, {'id': 'M14111', 'name': 'Precancerous Conditions', 'relevance': 'LOW'}, {'id': 'T1074', 'name': 'Cervical Intraepithelial Neoplasia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}\n",
      "{'protocolSection': {'identificationModule': {'nctId': 'NCT05591079', 'orgStudyIdInfo': {'id': 'NASH-CS0159-002'}, 'organization': {'fullName': 'Cascade Pharmaceuticals, Inc', 'class': 'OTHER'}, 'briefTitle': 'A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH', 'officialTitle': 'A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of CS0159 in the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH)'}, 'statusModule': {'statusVerifiedDate': '2023-07', 'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-02-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-11-09', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-11-09', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2022-10-09', 'studyFirstSubmitQcDate': '2022-10-20', 'studyFirstPostDateStruct': {'date': '2022-10-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-20', 'lastUpdatePostDateStruct': {'date': '2023-11-21', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Cascade Pharmaceuticals, Inc', 'class': 'OTHER'}, 'collaborators': [{'name': 'Laboratory Corporation of America', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)', 'detailedDescription': 'This will be a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PKs, and efficacy of CS0159 in the treatment of patients with NASH over 12 weeks.'}, 'conditionsModule': {'conditions': ['Nonalcoholic Steatohepatitis (NASH)']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 99, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1.4mg CS0159', 'type': 'EXPERIMENTAL', 'description': 'One tablet daily for 12 weeks', 'interventionNames': ['Drug: CS0159 (Linafexor)']}, {'label': '2mg CS0159', 'type': 'EXPERIMENTAL', 'description': 'One tablet daily for 12 weeks', 'interventionNames': ['Drug: CS0159 (Linafexor)']}, {'label': 'PLACEBO', 'type': 'PLACEBO_COMPARATOR', 'description': 'One tablet daily for 12 weeks', 'interventionNames': ['Drug: CS0159 (Linafexor)']}], 'interventions': [{'type': 'DRUG', 'name': 'CS0159 (Linafexor)', 'description': 'Oral QD', 'armGroupLabels': ['1.4mg CS0159', '2mg CS0159', 'PLACEBO'], 'otherNames': ['placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'MRI-PDFF', 'description': 'To assess the changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12', 'timeFrame': 'Week 12'}, {'measure': 'Adverse events', 'description': 'To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks', 'timeFrame': 'Week 12'}], 'secondaryOutcomes': [{'measure': 'Cmax', 'description': 'maximum concentration (Cmax) from baseline to Week 12', 'timeFrame': 'week 6, week 12'}, {'measure': 'tmax', 'description': 'time to maximum plasma concentration (tmax) from baseline to Week 12', 'timeFrame': 'week 6, week 12'}, {'measure': 't1/2', 'description': 'half-life (t1/2) from baseline to Week 12', 'timeFrame': 'week 6, week 12'}, {'measure': 'AUC', 'description': 'accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to Week 12', 'timeFrame': 'week 6, week 12'}, {'measure': 'Pharmacodynamics (PD)', 'description': 'Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 and 7α-hydroxy-4-cholesten-3-one (C4) from baseline to Week 12', 'timeFrame': 'week 6, week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Patients who meet the diagnosis of NASH.\\n2. Evidence of metabolic syndrome, except for those patients with biopsy-proven NASH.\\n3. Body mass index (BMI) \\\\>25 kg/m2, NOTE: for Asian-Americans BMI \\\\>23 kg/m2.\\n4. Stable use of other antidiabetic, weight loss, or lipid-modifying medications for at least 12 weeks prior to randomization.\\n\\nExclusion Criteria:\\n\\n1. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer.\\n2. Previous exposure to farnesoid X receptor (FXR) agonists 3 months prior to the first dosing.\\n3. Current or within 6 months of screening use of drugs associated with steatosis, including but not limited to eg, methotrexate, amiodarone, high-dose estrogen, tamoxifen, long term systemic steroids, anabolic steroids, valproic acid.\\n4. Prothrombin time international normalized ratio \\\\>1.3, unless due to therapeutic anticoagulation.\\n5. Total bilirubin \\\\>upper limit of normal (ULN; except for patients with Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count).\\n\\n   Platelet count \\\\<140 000/mm³, absolute neutrophil count \\\\<1500 cells/mm3, or total\\n6. white blood cells \\\\<3000 cells/mm3.\\n7. Alanine aminotransferase and aspartate aminotransferase (AST) \\\\>5 × ULN, or alkaline phosphatase (ALP) \\\\>1.5 × ULN.\\n8. Weight changes \\\\>10% in 6 months prior to screening, or weight changes \\\\>5% from the screening MRI-PDFF to randomization or from the time of the diagnostic liver biopsy to randomization, whichever is longer.\\n9. Poorly controlled hypertension (systolic \\\\>160 mm Hg, or diastolic blood pressure \\\\>100 mm Hg - mean of 3 measurements).\\n10. Uncontrolled diabetes mellitus (hemoglobin A1c \\\\>10.0% during screening).\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Rong Deng', 'affiliation': 'Cascade Pharmaceuticals, Inc', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'National Research Institute - Gardena', 'city': 'Gardena', 'state': 'California', 'zip': '90247-3586', 'country': 'United States', 'geoPoint': {'lat': 33.88835, 'lon': -118.30896}}, {'facility': 'Velocity Clinical Research, Huntington Park', 'city': 'Huntington Park', 'state': 'California', 'zip': '90255-2959', 'country': 'United States', 'geoPoint': {'lat': 33.98168, 'lon': -118.22507}}, {'facility': 'Velocity Clinical Research - Panorama City', 'city': 'Panorama City', 'state': 'California', 'zip': '91402-3022', 'country': 'United States', 'geoPoint': {'lat': 34.22473, 'lon': -118.44981}}, {'facility': 'Velocity Clinical Research - Santa Ana', 'city': 'Santa Ana', 'state': 'California', 'zip': '92704', 'country': 'United States', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'facility': 'Ocala GI Research', 'city': 'Lady Lake', 'state': 'Florida', 'zip': '32159', 'country': 'United States', 'geoPoint': {'lat': 28.91749, 'lon': -81.92286}}, {'facility': 'Florida Research Institute', 'city': 'Lakewood', 'state': 'Florida', 'zip': '34211-4930', 'country': 'United States'}, {'facility': 'Floridian Clinical Research, LLC - Miami Lakes', 'city': 'Miami Lakes', 'state': 'Florida', 'zip': '33016-1518', 'country': 'United States', 'geoPoint': {'lat': 25.90871, 'lon': -80.30866}}, {'facility': 'San Marcus Research Clinic, Inc - Miami', 'city': 'Miami', 'state': 'Florida', 'zip': '33014-5602', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Gastroenterology Associates of Ocala', 'city': 'Ocala', 'state': 'Florida', 'zip': '34471', 'country': 'United States', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'facility': 'Oracle Clinical Research', 'city': 'College Park', 'state': 'Georgia', 'zip': '30349', 'country': 'United States', 'geoPoint': {'lat': 33.65344, 'lon': -84.44937}}, {'facility': 'Metropolitan Gastroenterology Associates - Westbank Office and Endoscopy', 'city': 'Marrero', 'state': 'Louisiana', 'zip': '70072', 'country': 'United States', 'geoPoint': {'lat': 29.89937, 'lon': -90.10035}}, {'facility': 'Raja M. Din MD, PLLC - Gastroenterology & Hepatology', 'city': 'Greenbelt', 'state': 'Maryland', 'zip': '20770-6702', 'country': 'United States', 'geoPoint': {'lat': 39.00455, 'lon': -76.87553}}, {'facility': 'Lucas Research', 'city': 'Morehead City', 'state': 'North Carolina', 'zip': '28557', 'country': 'United States', 'geoPoint': {'lat': 34.72294, 'lon': -76.72604}}, {'facility': 'Texas Liver Institute (TLI) - Austin', 'city': 'Austin', 'state': 'Texas', 'zip': '78757-7571', 'country': 'United States', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'facility': 'Pioneer Research Solutions Inc - Houston - Stancliff Rd', 'city': 'Houston', 'state': 'Texas', 'zip': '77099-4307', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'The Texas Liver Institute, Inc.', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78215', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'Clinical Trials of Texas, LLC', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-29'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000005234', 'term': 'Fatty Liver'}, {'id': 'D000065626', 'term': 'Non-alcoholic Fatty Liver Disease'}], 'ancestors': [{'id': 'D000008107', 'term': 'Liver Diseases'}, {'id': 'D000004066', 'term': 'Digestive System Diseases'}], 'browseLeaves': [{'id': 'M8375', 'name': 'Fatty Liver', 'asFound': 'Steatohepatitis', 'relevance': 'HIGH'}, {'id': 'M11107', 'name': 'Liver Diseases', 'relevance': 'LOW'}, {'id': 'M30540', 'name': 'Non-alcoholic Fatty Liver Disease', 'asFound': 'Nonalcoholic Steatohepatitis', 'relevance': 'HIGH'}, {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'}, {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'}, {'id': 'T5868', 'name': 'Visceral Steatosis', 'asFound': 'Steatohepatitis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC06', 'name': 'Digestive System Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}\n"
     ]
    }
   ],
   "source": [
    "for item in response.json()[\"studies\"]:\n",
    "    print(item)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
